DEF: Ocean Biomedical Seeks Stockholder Approval for Reverse Stock Split, New Incentive Plan, and Director Elections

Ocean Biomedical is asking stockholders to approve a reverse stock split, a new incentive plan, and the election of directors at its upcoming annual meeting.

Summary

• Ocean Biomedical, Inc. is holding its 2024 annual meeting of stockholders on March 28, 2025.
• Stockholders will vote on several proposals, including the election of directors, a reverse stock split authorization (1:2 to 1:250), a new Company Incentive Plan, ratification of the appointment of Berkowitz Pollack Brant, CPAs as the company's independent registered public accounting firm for the year ended December 31, 2024, and advisory votes on executive compensation.
• The Board of Directors unanimously recommends voting FOR the Nasdaq Proposal.
• The record date for determining stockholders eligible to vote at the Annual Meeting is February 21, 2025.
• The company is seeking approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement of $1 per share.
• Ocean Biomedical received a letter from Nasdaq on December 3, 2024, indicating non-compliance with the minimum bid price rule.
• The company has a compliance period until June 2, 2025, to regain compliance.
• The company is also seeking approval for a new 2025 Equity Incentive Plan with 30,000,000 shares reserved for issuance.
• The company is also seeking to ratify the appointment of Berkowitz Pollock Brant, CPAs as the company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
• The company is also seeking advisory votes on the frequency of future advisory votes on executive compensation and on the approval of compensation of our named executive officers.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. The need for a reverse stock split indicates financial challenges, but the new incentive plan and other proposals suggest a focus on future growth. The overall sentiment is neutral.

Positives

• The company is taking steps to regain compliance with Nasdaq listing requirements.
• The proposed Equity Incentive Plan aims to attract and retain key personnel.
• The company is engaging with stockholders on important governance matters.

Negatives

• The company is not in compliance with Nasdaq's minimum bid price requirement.
• The company is proposing a reverse stock split, which can be viewed negatively by investors.
• The company is controlled by its founder, which may limit shareholder influence.

Risks

• The reverse stock split may not increase the stock price or maintain it at a higher level.
• The reverse stock split may decrease the liquidity of the stock.
• The company may face delisting from Nasdaq if it does not regain compliance with the minimum bid price rule.
• Current stockholders will likely experience dilution as a result of the Reverse Stock Split.
• There is a trend for our stock price to decrease after a reverse stock split.

Future Outlook

The company is focused on regaining compliance with Nasdaq listing requirements and implementing its strategic plans.

Management Comments

• The Board of Directors strongly believes that the reverse stock split is necessary for the future viability of the Company.
• The Board of Directors recommends that you vote FOR approval of the compensation of our named executive officers as disclosed in in the proxy statement set forth under the caption [insert appropriate reference] of this proxy statement.

Industry Context

Reverse stock splits are often used by companies facing delisting to increase their stock price and maintain their listing on major exchanges. Equity incentive plans are common tools for attracting and retaining talent in the competitive biotechnology industry.

Comparison to Industry Standards

• Comparable companies that have recently undertaken reverse stock splits include Xometry, Inc. (XMTR) and Cyngnal Inc. (CYN).
• The size of the proposed equity incentive plan (30,000,000 shares) is within the typical range for companies of Ocean Biomedical's size and stage of development.
• The terms of the proposed equity incentive plan are generally consistent with industry standards, including provisions for stock options, restricted stock units, and performance-based awards.

Management Changes

Corporate Governance

Related Party Transactions

• License Agreements with Elkurt, Inc., a company formed by Legacy Oceans scientific co-founders and members of our board of directors Jack A. Elias, M.D., former Dean of Medicine and current Special Advisor for Health Affairs to Brown University, and Jonathan Kurtis, M.D., PhD, Chair of the Department of Pathology and Laboratory Medicine at Brown University.
• Consulting Agreement with Jonathan Kurtis, a member of its board of directors.
• Advisor Agreement with Dr. Jack Elias, a member of Legacy Oceans board of directors.

Stakeholder Impact

• Stockholders may experience dilution if the reverse stock split is implemented and the company issues more shares.
• Employees may benefit from the new Equity Incentive Plan.
• The company's ability to maintain its Nasdaq listing is important for its long-term viability.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on March 28, 2025.
• The company will implement the reverse stock split if approved by stockholders and deemed advisable by the Board.
• The company will implement the new Equity Incentive Plan if approved by stockholders.
• The company will continue to work towards regaining compliance with Nasdaq listing requirements.

Key Dates